mercoledì 20 maggio 2020

FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumour - Efficacy for evidence was evaluated in the INVICTUS study

Fonte: ESMO European Society for Medical Oncology

Link all'articolo completo